Compare Pfizer with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs IPCA LABS - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER IPCA LABS PFIZER/
IPCA LABS
 
P/E (TTM) x 49.3 23.6 209.2% View Chart
P/BV x 8.2 8.4 97.1% View Chart
Dividend Yield % 0.4 0.1 290.3%  

Financials

 PFIZER   IPCA LABS
EQUITY SHARE DATA
    PFIZER
Mar-19
IPCA LABS
Mar-19
PFIZER/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3,8401,042 368.5%   
Low Rs2,080590 352.5%   
Sales per share (Unadj.) Rs455.0298.6 152.4%  
Earnings per share (Unadj.) Rs93.835.0 267.9%  
Cash flow per share (Unadj.) Rs109.449.4 221.3%  
Dividends per share (Unadj.) Rs22.503.00 750.0%  
Dividend yield (eoy) %0.80.4 206.8%  
Book value per share (Unadj.) Rs658.2247.1 266.4%  
Shares outstanding (eoy) m45.75126.35 36.2%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x6.52.7 238.1%   
Avg P/E ratio x31.623.3 135.4%  
P/CF ratio (eoy) x27.116.5 163.9%  
Price / Book Value ratio x4.53.3 136.2%  
Dividend payout %24.08.6 279.9%   
Avg Mkt Cap Rs m135,420103,108 131.3%   
No. of employees `0002.613.4 19.6%   
Total wages/salary Rs m3,2387,874 41.1%   
Avg. sales/employee Rs Th7,911.42,807.0 281.8%   
Avg. wages/employee Rs Th1,230.9585.8 210.1%   
Avg. net profit/employee Rs Th1,630.7329.0 495.7%   
INCOME DATA
Net Sales Rs m20,81537,732 55.2%  
Other income Rs m1,674577 290.2%   
Total revenues Rs m22,48938,309 58.7%   
Gross profit Rs m5,7126,901 82.8%  
Depreciation Rs m7141,824 39.1%   
Interest Rs m73189 38.6%   
Profit before tax Rs m6,5995,465 120.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,3091,042 221.5%   
Profit after tax Rs m4,2914,422 97.0%  
Gross profit margin %27.418.3 150.0%  
Effective tax rate %35.019.1 183.4%   
Net profit margin %20.611.7 175.9%  
BALANCE SHEET DATA
Current assets Rs m27,16723,778 114.3%   
Current liabilities Rs m8,91710,975 81.2%   
Net working cap to sales %87.733.9 258.4%  
Current ratio x3.02.2 140.6%  
Inventory Days Days68104 65.4%  
Debtors Days Days3066 45.7%  
Net fixed assets Rs m8,86220,368 43.5%   
Share capital Rs m458253 181.0%   
"Free" reserves Rs m29,65630,971 95.8%   
Net worth Rs m30,11331,224 96.4%   
Long term debt Rs m251,409 1.8%   
Total assets Rs m39,40045,507 86.6%  
Interest coverage x91.530.0 305.5%   
Debt to equity ratio x00 1.8%  
Sales to assets ratio x0.50.8 63.7%   
Return on assets %11.110.1 109.3%  
Return on equity %14.214.2 100.6%  
Return on capital %22.117.3 127.8%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m42817,308 2.5%   
Fx outflow Rs m7866,266 12.5%   
Net fx Rs m-35811,042 -3.2%   
CASH FLOW
From Operations Rs m9784,923 19.9%  
From Investments Rs m351-1,563 -22.5%  
From Financial Activity Rs m-1,099-1,832 60.0%  
Net Cashflow Rs m2311,528 15.1%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 11.4 65.8%  
FIIs % 4.9 25.3 19.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.4 136.2%  
Shareholders   85,207 36,892 231.0%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ORCHID PHARMA  WYETH  ASTRAZENECA PHARMA  VENUS REMEDIES  CIPLA  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 296 Points Higher; Coal India, UPL & Hindalco Surge Over 6%(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


May 10, 2021 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS